Signed in as:
filler@godaddy.com
Lutetium
Current Status of 177 Lu-PSMA Targeted Therapies and Where Will We Be In the Near Future
ESMO 2019: Preliminary Results of a Phase I/II Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC
Phase I/II Trial of Lutetium-177–PSMA-617 Plus Idronoxil in Metastatic Castration-Resistant Prostate Cancer
PSMA PET During Lu-177–PSMA Radioligand Therapy May Help Guide Treatment
Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
Actinium
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Clinical Experience on 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients: Safety and Efficacy Results
IODINE
Iodine Symporter Targeting with 124I/131I Theranostics
¹³¹I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications
MIBG in Neuroblastoma Diagnostic Imaging and Therapy.
ZIRCONIUM
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry